GM-CSF, IL-3, and IL-5 Family of Cytokines: Regulators of Inflammation.

[1]  Pancreatic Neoplasia , 2019, Yamada's Handbook of Gastroenterology.

[2]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[3]  Wenjie Zhu,et al.  Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis , 2018, The Journal of clinical investigation.

[4]  B. Stockinger,et al.  Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis , 2018, Immunity.

[5]  S. Kaveri,et al.  Regulatory T cells induce activation rather than suppression of human basophils , 2018, Science Immunology.

[6]  D. Neuberg,et al.  PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF , 2018, Cancer Immunology Research.

[7]  J. Kremer,et al.  Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody , 2018, Arthritis & rheumatology.

[8]  A. Huber,et al.  GM-CSF Promotes Chronic Disability in Experimental Autoimmune Encephalomyelitis by Altering the Composition of Central Nervous System–Infiltrating Cells, but Is Dispensable for Disease Induction , 2018, The Journal of Immunology.

[9]  M. Dottore,et al.  A dual role for the N-terminal domain of the IL-3 receptor in cell signalling , 2018, Nature Communications.

[10]  P. Libby,et al.  The infarcted myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes , 2017, The Journal of experimental medicine.

[11]  M. Satoh,et al.  Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5. , 2017, Cytokine.

[12]  I. Pavord,et al.  Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.

[13]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[14]  S. Yancey,et al.  Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.

[15]  I. Komuro,et al.  A heart–brain–kidney network controls adaptation to cardiac stress through tissue macrophage activation , 2017, Nature Medicine.

[16]  B. Becher,et al.  Dysregulation of the Cytokine GM‐CSF Induces Spontaneous Phagocyte Invasion and Immunopathology in the Central Nervous System , 2017, Immunity.

[17]  J. Kremer,et al.  A randomised phase IIb study of mavrilimumab, a novel GM–CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[18]  S. Ziegler,et al.  GM-CSF produced by the airway epithelium is required for sensitization to cockroach allergen , 2016, Mucosal Immunology.

[19]  H. Kaufman,et al.  Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma , 2017, American Journal of Clinical Dermatology.

[20]  Burkhard Becher,et al.  GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. , 2016, Immunity.

[21]  M. Cassatella,et al.  Synergistic production of TNFα and IFNα by human pDCs incubated with IFNλ3 and IL-3. , 2016, Cytokine.

[22]  C. Lemière,et al.  Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.

[23]  I. Puzanov,et al.  Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Michael W Parker,et al.  Conformational Changes in the GM-CSF Receptor Suggest a Molecular Mechanism for Affinity Conversion and Receptor Signaling. , 2016, Structure.

[25]  T. Welling,et al.  GM-CSF Mediates Mesenchymal-Epithelial Cross-talk in Pancreatic Cancer. , 2016, Cancer discovery.

[26]  Xiaodi Wu,et al.  Distinct Transcriptional Programs Control Cross-Priming in Classical and Monocyte-Derived Dendritic Cells. , 2016, Cell reports.

[27]  W. Garrett,et al.  Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut , 2016, Science.

[28]  R. Locksley,et al.  Tuft-cell-derived IL-25 regulates an intestinal ILC2–epithelial response circuit , 2015, Nature.

[29]  F. Gao,et al.  Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. , 2016, Blood.

[30]  Michael J. Wilson,et al.  CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors , 2015, mAbs.

[31]  M. Cassatella,et al.  Synergistic production of TNF a and IFN a by human pDCs incubated with IFN k 3 and IL-3 , 2016 .

[32]  A. Roberts,et al.  Targeting GM-CSF in inflammatory diseases , 2016, Nature Reviews Rheumatology.

[33]  Steven G. Smith,et al.  Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent. , 2015, The Journal of allergy and clinical immunology.

[34]  B. Becher,et al.  The Cytokine GM-CSF Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses Autoimmunity. , 2015, Immunity.

[35]  S. Corey,et al.  G-CSF and GM-CSF in Neutropenia , 2015, The Journal of Immunology.

[36]  E. Radue,et al.  Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[37]  A. Giobbie-Hurder,et al.  Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma , 2015, Cancer Immunology Research.

[38]  I. Kerridge,et al.  A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.

[39]  E. Jaffee,et al.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Foell,et al.  Reprogramming of Monocytes by GM-CSF Contributes to Regulatory Immune Functions during Intestinal Inflammation , 2015, The Journal of Immunology.

[41]  Yechen Xiao,et al.  CD123 and its potential clinical application in leukemias. , 2015, Life sciences.

[42]  J. Campbell,et al.  Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[43]  J. Kirkwood,et al.  Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.

[44]  D. Ollis,et al.  Crystal structure of the mouse interleukin-3 β-receptor: insights into interleukin-3 binding and receptor activation. , 2014, The Biochemical journal.

[45]  M. Kurrer,et al.  Induction of the nuclear receptor PPAR-γ by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages , 2014, Nature Immunology.

[46]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[47]  Hyun-Dong Chang,et al.  IL-17 and GM-CSF Expression Are Antagonistically Regulated by Human T Helper Cells , 2014, Science Translational Medicine.

[48]  R. Weissleder,et al.  Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis , 2014, The Journal of experimental medicine.

[49]  H. Yao,et al.  A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. , 2014, Cancer cell.

[50]  H. Ramshaw,et al.  Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC , 2014, Leukemia.

[51]  Hong-Wei Sun,et al.  Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients , 2014, Proceedings of the National Academy of Sciences.

[52]  Angel F. Lopez,et al.  Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362. , 2014, Acta crystallographica. Section F, Structural biology communications.

[53]  S. Leibundgut-Landmann,et al.  IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. , 2014, Immunity.

[54]  Bernard Malissen,et al.  Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF , 2013, The Journal of experimental medicine.

[55]  Dan Knights,et al.  Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome , 2013, Gut.

[56]  B. Prabhakar,et al.  OX40L/Jagged1 Cosignaling by GM-CSF–Induced Bone Marrow-Derived Dendritic Cells Is Required for the Expansion of Functional Regulatory T Cells , 2013, The Journal of Immunology.

[57]  C. Suh,et al.  Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm , 2013, Histopathology.

[58]  Angel F. Lopez,et al.  Targeting of acute myeloid leukaemia by cytokine‐induced killer cells redirected with a novel CD123‐specific chimeric antigen receptor , 2013, British journal of haematology.

[59]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[60]  Angel F. Lopez,et al.  The GM–CSF/IL‐3/IL‐5 cytokine receptor family: from ligand recognition to initiation of signaling , 2012, Immunological reviews.

[61]  M. Merad,et al.  GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. , 2012, Immunity.

[62]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[63]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[64]  S. Yokoyama,et al.  Structural basis of interleukin‐5 dimer recognition by its α receptor , 2012, Protein science : a publication of the Protein Society.

[65]  S. Wenzel.  Asthma phenotypes: the evolution from clinical to molecular approaches , 2012, Nature Medicine.

[66]  R. Weissleder,et al.  Innate Response Activator B Cells Protect Against Microbial Sepsis , 2012, Science.

[67]  A. Kotzsch,et al.  Structure analysis of the IL-5 ligand-receptor complex reveals a wrench-like architecture for IL-5Rα. , 2011, Structure.

[68]  J. Hamilton,et al.  Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. , 2011, Arthritis and rheumatism.

[69]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[70]  D. Neuberg,et al.  A dual role for the immune response in a mouse model of inflammation-associated lung cancer. , 2011, The Journal of clinical investigation.

[71]  B. Prabhakar,et al.  GM‐CSF‐induced, bone‐marrow‐derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms , 2011, Journal of leukocyte biology.

[72]  N. Hacohen,et al.  IAP inhibitors enhance co-stimulation to promote tumor immunity , 2010, The Journal of experimental medicine.

[73]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[74]  Irah L. King,et al.  GM-CSF–dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization , 2010, The Journal of experimental medicine.

[75]  Anna L. Brown,et al.  Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. , 2010, Blood.

[76]  P. Libby,et al.  Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites , 2009, Science.

[77]  J. Dick,et al.  Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.

[78]  D. Simone,et al.  Hematopoietic colony–stimulating factors mediate tumor-nerve interactions and bone cancer pain , 2009, Nature Medicine.

[79]  G. Dranoff,et al.  Milk fat globule epidermal growth factor–8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms , 2009, The Journal of experimental medicine.

[80]  Lin Chen,et al.  A Cytokine–Cytokine Interaction in the Assembly of Higher-Order Structure and Activation of the Interleukine-3:Receptor Complex , 2009, PloS one.

[81]  Irah L. King,et al.  Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. , 2009, Blood.

[82]  Hong Zhang,et al.  Multiple roles of Lyn kinase in myeloid cell signaling and function , 2009, Immunological reviews.

[83]  S. Ford,et al.  A New Isoform of Interleukin-3 Receptor α with Novel Differentiation Activity and High Affinity Binding Mode* , 2009, Journal of Biological Chemistry.

[84]  K. Takatsu,et al.  Interleukin 5 in the link between the innate and acquired immune response. , 2009, Advances in immunology.

[85]  M. Dottore,et al.  The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation , 2008, Cell.

[86]  I. Chaiken,et al.  Interleukin-5 Receptor Subunit Oligomerization and Rearrangement Revealed by Fluorescence Resonance Energy Transfer Imaging* , 2008, Journal of Biological Chemistry.

[87]  I. Chaiken,et al.  Slow-dissociation effect of common signaling subunit beta c on IL5 and GM-CSF receptor assembly. , 2008, Cytokine.

[88]  L. Santambrogio,et al.  GMCSF in the absence of other cytokines sustains human dendritic cell precursors with T cell regulatory activity and capacity to differentiate into functional dendritic cells. , 2008, Immunology letters.

[89]  D. Neuberg,et al.  Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. , 2007, Blood.

[90]  D. Carrasco,et al.  MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. , 2007, The Journal of clinical investigation.

[91]  A. Burgess,et al.  Mice Lacking Three Myeloid Colony-Stimulating Factors (G-CSF, GM-CSF, and M-CSF) Still Produce Macrophages and Granulocytes and Mount an Inflammatory Response in a Sterile Model of Peritonitis1 , 2007, The Journal of Immunology.

[92]  M. Kavuru,et al.  An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. , 2006, Chest.

[93]  D. Ollis,et al.  An improved resolution structure of the human beta common receptor involved in IL-3, IL-5 and GM-CSF signalling which gives better definition of the high-affinity binding epitope. , 2006, Acta crystallographica. Section F, Structural biology and crystallization communications.

[94]  C. Begley,et al.  Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch , 2006, The EMBO journal.

[95]  R. Seeley,et al.  GM-CSF action in the CNS decreases food intake and body weight. , 2005, The Journal of clinical investigation.

[96]  J. Korzenik,et al.  Sargramostim for active Crohn's disease. , 2005, The New England journal of medicine.

[97]  Angel F. Lopez,et al.  The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. , 2004, Blood.

[98]  A. Irvine,et al.  Measurement of colony-stimulating factors in synovial fluid: potential clinical value , 2004, Rheumatology International.

[99]  J. Dick,et al.  Human acute myeloid leukemia stem cells. , 2003, Archives of medical research.

[100]  F. Alt,et al.  Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer , 2003, The Journal of experimental medicine.

[101]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[102]  A. Whetton,et al.  Identification of primary structural features that define the differential actions of IL-3 and GM-CSF receptors. , 2002, Blood.

[103]  A. Masuda,et al.  Th2 Cytokine Production from Mast Cells Is Directly Induced by Lipopolysaccharide and Distinctly Regulated by c-Jun N-Terminal Kinase and p38 Pathways1 , 2002, The Journal of Immunology.

[104]  Emma Evergren,et al.  Biosensor analysis of dynamics of interleukin 5 receptor subunit βc interaction with IL5:IL5Rα complexes , 2002 .

[105]  Ian Walker,et al.  Structure of the Complete Extracellular Domain of the Common β Subunit of the Human GM-CSF, IL-3, and IL-5 Receptors Reveals a Novel Dimer Configuration , 2001, Cell.

[106]  M. Dottore,et al.  Site-specific serine phosphorylation of the IL-3 receptor is required for hemopoietic cell survival. , 2000, Molecular cell.

[107]  J. Stoller,et al.  Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. , 2000, American journal of respiratory and critical care medicine.

[108]  Sumiko Watanabe,et al.  Association of Lyn tyrosine kinase to the GM‐CSF and IL‐3 receptor common βc subunit and role of Src tyrosine kinases in DNA synthesis and anti‐apoptosis , 2000, Genes to cells : devoted to molecular & cellular mechanisms.

[109]  K. Schulman,et al.  Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[111]  A. Ballestrero,et al.  Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  S. Stafford,et al.  The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptor. , 1999, Journal of immunology.

[113]  H. Kiyono,et al.  Deficiency of IL-5 receptor alpha-chain selectively influences the development of the common mucosal immune system independent IgA-producing B-1 cell in mucosa-associated tissues. , 1999, Journal of immunology.

[114]  C. Porta,et al.  Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. , 1999, Haematologica.

[115]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[116]  V. Provitera,et al.  Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. , 1998, Immunopharmacology and immunotoxicology.

[117]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[118]  J. Marine,et al.  Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors , 1998, Cell.

[119]  G. Dranoff,et al.  Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites , 1998, Nature.

[120]  M. Mihm,et al.  Involvement of interleukin-3 in delayed-type hypersensitivity. , 1998, Blood.

[121]  Q. Sun,et al.  Identification of a Cys Motif in the Common β Chain of the Interleukin 3, Granulocyte-Macrophage Colony-stimulating Factor, and Interleukin 5 Receptors Essential for Disulfide-linked Receptor Heterodimerization and Activation of All Three Receptors* , 1998, The Journal of Biological Chemistry.

[122]  M. Elliott,et al.  The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor exists as a preformed receptor complex that can be activated by GM-CSF, interleukin-3, or interleukin-5. , 1997, Blood.

[123]  C. Mcwherter,et al.  The Receptor Binding Site of Human Interleukin-3 Defined by Mutagenesis and Molecular Modeling* , 1997, The Journal of Biological Chemistry.

[124]  S. Barry,et al.  Roles of the N and C Terminal Domains of the Interleukin-3 Receptor α Chain in Receptor Function , 1997 .

[125]  G. Goodall,et al.  Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor function. , 1997, Blood.

[126]  M. Mihm,et al.  A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. , 1997, Human gene therapy.

[127]  K. Diederichs,et al.  Refined crystal structure and mutagenesis of human granulocyte‐macrophage colony‐stimulating factor , 1996, Proteins.

[128]  C. Bagley,et al.  A Single Tyrosine Residue in the Membrane-proximal Domain of the Granulocyte-Macrophage Colony-stimulating Factor, Interleukin (IL)-3, and IL-5 Receptor Common β-Chain Is Necessary and Sufficient for High Affinity Binding and Signaling by All Three Ligands* , 1996, The Journal of Biological Chemistry.

[129]  R. Nishinakamura,et al.  Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. , 1996, Blood.

[130]  C. Mcwherter,et al.  Three-dimensional solution structure and backbone dynamics of a variant of human interleukin-3. , 1996, Journal of molecular biology.

[131]  J. Miyazaki,et al.  Defective B-1 cell development and impaired immunity against Angiostrongylus cantonensis in IL-5R alpha-deficient mice. , 1996, Immunity.

[132]  G. Dranoff,et al.  Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. , 1996, The American journal of physiology.

[133]  A. Tolcher,et al.  Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. , 1996, Blood.

[134]  G. Dranoff,et al.  Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. , 1996, The Journal of clinical investigation.

[135]  P. Hodgkin,et al.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. , 1996, Immunity.

[136]  W. Busse,et al.  Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: comparison with airway eosinophils. , 1995, The Journal of allergy and clinical immunology.

[137]  J. Tavernier,et al.  Characterization of critical residues in the cytoplasmic domain of the human interleukin‐5 receptor α chain required for growth signal transduction , 1995, European journal of immunology.

[138]  S. Carr,et al.  Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. , 1995, The Journal of biological chemistry.

[139]  R. Nishinakamura,et al.  Mice deficient for the IL-3/GM-CSF/IL-5 βc receptor exhibit lung pathology and impaired immune response, while βIL3 receptor-deficient mice are normal , 1995 .

[140]  M. Ichihara,et al.  Impaired interleukin‐3 (IL‐3) response of the A/J mouse is caused by a branch point deletion in the IL‐3 receptor alpha subunit gene. , 1995, The EMBO journal.

[141]  K. Arai,et al.  Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. , 1995, Immunity.

[142]  K. Takatsu,et al.  A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction , 1994, Molecular and cellular biology.

[143]  M. Lambert,et al.  The Three‐Dimensional Structure of Human Interleukin‐5 at 2.4‐Angstroms Resolution: Implication for the Structures of Other Cytokines , 1994, Annals of the New York Academy of Sciences.

[144]  M. F. Shannon,et al.  Specific human granulocyte-macrophage colony-stimulating factor antagonists. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[145]  A. Dunn,et al.  Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[146]  G. Dranoff,et al.  Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. , 1994, Science.

[147]  M. Doyle,et al.  Analysis of the interaction between human interleukin‐5 and the soluble domain of its receptor using a surface plasmon resonance biosensor , 1994, Journal of molecular recognition : JMR.

[148]  B. Druker,et al.  Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the alpha and beta subunits. , 1993, Blood.

[149]  L. Lichtenstein,et al.  GM-CSF regulates human eosinophil responses to F-Met peptide and platelet activating factor. , 1993, Journal of immunology.

[150]  Y. Okayama,et al.  Comparison of mechanisms of IL‐3 induced histamine release and IL‐3 priming effect on human basophils , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[151]  J. Cleveland,et al.  Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[152]  M. Lambert,et al.  A novel dimer configuration revealed by the crystal structure at 2.4 Å resolution of human interleukin-5 , 1993, Nature.

[153]  L. Koenderman,et al.  Granulocyte-macrophage colony-stimulating factor induces sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, hFc gamma RII, on human eosinophils. , 1993, Blood.

[154]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[155]  M. F. Shannon,et al.  A human interleukin 3 analog with increased biological and binding activities. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[156]  A. Miyajima,et al.  Critical cytoplasmic domains of the common beta subunit of the human GM‐CSF, IL‐3 and IL‐5 receptors for growth signal transduction and tyrosine phosphorylation. , 1992, The EMBO journal.

[157]  P. Morrissey,et al.  Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[158]  A. Miyajima,et al.  Two distinct functional high affinity receptors for mouse interleukin‐3 (IL‐3). , 1992, The EMBO journal.

[159]  A. Ganser,et al.  Clinical Effects of Recombinant Human Interleukin‐3 , 1991, American Journal of Clinical Oncology.

[160]  J. Tavernier,et al.  A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific α chain and a β chain shared with the receptor for GM-CSF , 1991, Cell.

[161]  K. Arai,et al.  Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors , 1991, Cell.

[162]  S. Barry,et al.  Structure‐function analysis of interleukin‐5 utilizing mouse/human chimeric molecules. , 1991, The EMBO journal.

[163]  N. Yamaguchi,et al.  In vivo administration of antibody to murine IL-5 receptor inhibits eosinophilia of IL-5 transgenic mice. , 1991, International immunology.

[164]  K. Arai,et al.  Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[165]  K. Arai,et al.  Cloning and expression of a gene encoding an interleukin 3 receptor-like protein: identification of another member of the cytokine receptor gene family. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[166]  K. Arai,et al.  Cloning of an interleukin-3 receptor gene: a member of a distinct receptor gene family. , 1990, Science.

[167]  松本 良二.  Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells , 1990 .

[168]  D. Gearing,et al.  Expression cloning of a receptor for human granulocyte‐macrophage colony‐stimulating factor. , 1989, The EMBO journal.

[169]  A. D. de Weck,et al.  Interleukin 3-dependent mediator release in basophils triggered by C5a , 1989, The Journal of experimental medicine.

[170]  D. Metcalf,et al.  The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells , 1989, Nature.

[171]  N. Yamaguchi,et al.  Interleukin-5 induces maturation but not class switching of surface IgA-positive B cells into IgA-secreting cells. , 1989, Immunology.

[172]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[173]  R. Coffman,et al.  Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[174]  I. G. Young,et al.  Molecular cloning, nucleotide sequence, and expression of the gene encoding human eosinophil differentiation factor (interleukin 5). , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[175]  C. Begley,et al.  Hemopoietic responses in mice injected with purified recombinant murine GM-CSF. , 1987, Experimental hematology.

[176]  T. Kinashi,et al.  Cloning of cDNA for human T-cell replacing factor (interleukin-5) and comparison with the murine homologue. , 1986, Nucleic acids research.

[177]  T. Honjo,et al.  Cloning of complementary DNA encoding T-cell replacing factor and identity with B-cell growth factor II , 1986, Nature.

[178]  Yu-Chung Yang,et al.  Human IL-3 (multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3 , 1986, Cell.

[179]  C. Begley,et al.  Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. , 1986, Blood.

[180]  V. Kindler,et al.  Stimulation of hematopoiesis in vivo by recombinant bacterial murine interleukin 3. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[181]  G. Klaus,et al.  Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[182]  M. Strath,et al.  Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures , 1985, The Journal of experimental medicine.

[183]  E. Brown,et al.  Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. , 1985, Science.

[184]  D. Warren,et al.  Production of a T-cell hybrid producing a lymphokine stimulating eosinophil differentiation. , 1985, Immunology.

[185]  E. Puré,et al.  T Cell‐Derived Lymphokines That Induce IgM and IgG Secretion in Activated Murine B Cells , 1984, Immunological reviews.

[186]  D. Cohen,et al.  Molecular cloning of cDNA for murine interleukin-3 , 1984, Nature.

[187]  A. Kelso,et al.  Molecular cloning of cDNA encoding a murine haematopoietic growth regulator, granulocyte—macrophage colony stimulating factor , 1984, Nature.

[188]  N. Nicola,et al.  Selective stimulation by mouse spleen cell conditioned medium of human eosinophil colony formation. , 1983, Blood.

[189]  S. Swain,et al.  Production of a B cell growth-promoting activity, (DL)BCGF, from a cloned T cell line and its assay on the BCL1 B cell tumor , 1982, The Journal of experimental medicine.

[190]  J. Ihle,et al.  Procedures for the purification of interleukin 3 to homogeneity. , 1982, Journal of immunology.

[191]  A. Tominaga,et al.  Antigen-induced T cell-replacing factor (TRF). I. Functional characterization of a TRF-producing helper T cell subset and genetic studies on TRF production. , 1980, Journal of immunology.

[192]  A. Burgess,et al.  Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. , 1977, The Journal of biological chemistry.

[193]  J. Parker,et al.  Formation of eosinophilic‐like granulocytic colonies by mouse bone marrow cells in vitro , 1974, Journal of cellular physiology.

[194]  L. Sachs,et al.  The induction of clones of normal mast cells by a substance from conditioned medium. , 1966, Experimental cell research.

[195]  D. Metcalf,et al.  The growth of mouse bone marrow cells in vitro. , 1966, The Australian journal of experimental biology and medical science.

[196]  J. Till,et al.  Cytological Demonstration of the Clonal Nature of Spleen Colonies Derived from Transplanted Mouse Marrow Cells , 1963, Nature.

[197]  J. Till,et al.  A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. , 1961, Radiation research.